New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
14:37 EDTVRTXVertex makes 'procedural' change to cystic fibrosis studies, TheStreet reports
Vertex Pharmaceuticals swapped the primary and secondary endpoints of two phase III trials investigating its combination cystic fibrosis therapy, making the primary endpoint of both studies the absolute change in lung function, though the company said it considers the move as "more procedural" than anything else and that it "was not based on anything going on in the study or anything observed in the study," reported TheStreet's Adam Feuerstein. Reference Link
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
09:06 EDTVRTXVertex names David Altshuler as Chief Scientific Officer
Subscribe for More Information
December 12, 2014
08:01 EDTVRTXPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 11, 2014
07:28 EDTVRTXCBI to hold a summit
2nd Specialty Data Optimization Summit is being held in Philadelphia on December 11.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use